Cyclerion Therapeutics Inc Market Cap ($2.25 Million)
Market Cap & Net Worth: Cyclerion Therapeutics Inc (CYCN)
Cyclerion Therapeutics Inc market cap. Cyclerion Therapeutics Inc (NASDAQ:CYCN) has a market capitalization of $2.25 Million ($2.25 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29902 globally and #6106 in its home market, demonstrating a 500.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cyclerion Therapeutics Inc's stock price $23.94 by its total outstanding shares 668764 (668.76K). Also see CYCN cash generation efficiency for how efficiently the company converts equity into cash flow.
Cyclerion Therapeutics Inc Market Cap History (2019–2026)
Cyclerion Therapeutics Inc market cap history from 2019 to 2026. Data shows change from $36.38 Million to $16.01 Million (-26.91% CAGR). Check CYCN stock price and chart for real-time trading data and today's change.
Index Memberships
Cyclerion Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #863 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2766 of 3165 |
Weight: Cyclerion Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cyclerion Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cyclerion Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Cyclerion Therapeutics Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.41x
Cyclerion Therapeutics Inc's market cap is 0.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $36.38 Million | $4.51 Million | -$123.01 Million | 8.07x | N/A |
| 2020 | $40.93 Million | $2.30 Million | -$77.80 Million | 17.83x | N/A |
| 2021 | $23.01 Million | $3.32 Million | -$51.65 Million | 6.93x | N/A |
| 2022 | $8.78 Million | $297.00K | -$44.08 Million | 29.55x | N/A |
| 2024 | $2.15 Million | $2.00 Million | -$3.06 Million | 1.08x | N/A |
| 2025 | $849.33K | $2.07 Million | -$3.53 Million | 0.41x | N/A |
Competitor Companies of CYCN by Market Capitalization
Companies near Cyclerion Therapeutics Inc in the global market cap rankings as of November 4, 2026. Also see CYCN current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Cyclerion Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Cyclerion Therapeutics Inc (2019–2026)
Market capitalization of Cyclerion Therapeutics Inc from 2019 to today. Between 2019 and today, Cyclerion Therapeutics Inc's market cap moved from $36.38 Million to $ 16.01 Million, with a yearly change of -26.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $16.01 Million | +1785.04% |
| 2025 | $849.33K | -60.56% |
| 2024 | $2.15 Million | -3.88% |
| 2023 | $2.24 Million | -74.47% |
| 2022 | $8.78 Million | -61.85% |
| 2021 | $23.01 Million | -43.79% |
| 2020 | $40.93 Million | +12.50% |
| 2019 | $36.38 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Cyclerion Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.25 Million USD |
| MoneyControl | $2.25 Million USD |
| MarketWatch | $2.25 Million USD |
| marketcap.company | $2.25 Million USD |
| Reuters | $2.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cyclerion Therapeutics Inc
As of September 8, 2026, Cyclerion Therapeutics, Inc. was acquired by Korsana Biosciences, Inc. in a reverse merger transaction. Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an oral… Read more